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Abstract 
There is still debate on what is the optimal follow-up protocol after a treatment for preinvasive 
cervical disease. We performed this study in order to improve diagnostic accuracy of the follow-up 
protocol and at the same time reducing the number of overtreated patients. One hundred and fourteen 
patients were followed up after conization for CIN3 and/or AIS at 3-6 month, 9-12 month and 18-24 
month intervals, then yearly. The follow-up consisted of cytology, colposcopy with biopsy if needed 
and HPV testing. The end-point of the study was a secondary treatment due to a high suspicion of 
resdidual/recurrent disease or disease free period of at least 24 months. The median follow-up time was 
41 months (5-72 months). In predicting residual/recurrent disease cytology had a specificity of 88.9%, 
sensitivity of 100%, PPV of 33.3% and a NPV of 100% whereas HPV had a specificity of 76.9%, 
sensitivity of 100%, PPV of 21.4% and a NPV of 100%. According to our results both tests can be used 
as a primary follow-up tool after conization. The choice should depend on a socio-economic aspect. In 
our setting the HPV test should be done only in those patients with a positive smear any time during 
follow-up as the point of decision for a second treatment. With this approach we could considerably 
decrease the number of reoperated patients and co-morbidities. 
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Introduction 
The fact that up to 30% of women treated for a preinvasive cervical disease are diagnosed 
with a residual/recurrent disease including an invasive carcinoma during follow-up, requires close 
surveillance of these patients [1]. The majority of cases (80-90%) are detected during the first two 
years after conization [2]. This in part justifies the anxiety of patients and gynecologists in fearing 
insufficient treatment or recurrence of the disease and that can lead to over-surveillance and 
overtreatment. We must keep in mind that these patients are mostly of childbearing age and desire 
preservation of fertility. Repeated treatments on the cervix can cause negative sequelae in their 
reproductive health [3]. 
Cytology, colposcopy and HPV testing during the follow-up have some downfalls compared 
to primary screening. Removal of the transformation zone at conization and scarring after surgery often 
makes colposcopy unsatisfactory and unreliable, especially when the cold-knife method is used [4]. 
Cytology is burdened with reparative and proliferative healing process of the epithelium. Conization 
removes the dysplastic lesion but not necessarily all the normal epithelium infected by HPV. Being 
aware of this we must use these tools in the best cost-effective protocol, which will be most accurate in 
diagnosis and sparing in treatment. Studies have shown a higher sensitivity in detection of 
residual/recurrent disease with the use of combined testing (cytology and HPV) [5,6]. Combined 
testing raises the cost of follow-up and in some countries like Croatia, with a tradition of high quality 
cytology this is unacceptable. Therefore we performed this study with intention to improve diagnostic 
accuracy of the follow-up protocol after conization keeping it safe and cost-effective and at the same 
time reducing the number of overtreated patients. 
 
 
 
 
 
 
 
 
 
 4 
Materials and methods 
The study was conducted at the Department of Obstetrics and Gynecology, University 
Hospital in Zagreb from 1
st
 January 2008 until 1
st
 January 2014. One hundred and thirty five patients 
treated with cold-knife conization (CKC) or large loop excision of the transformation zone (LLETZ) 
for a preinvasive cervical disease, were enrolled in the study. The study inclusion criteria were: cervical 
intraepithelial neoplasia grade 3 (CIN3) and/or adenocarcinoma in situ (AIS) confirmed at conization; 
no previous history of cervical pathology; not pregnant; no concomitant cancer or immunosuppressive 
disease. All of the participants signed an informed consent before entering the study. Control visits 
were scheduled at 3-6 month, 9-12 month and 18-24 month intervals. If testing results were negative 
during the first two years, follow up visits were re-scheduled yearly. The follow-up consisted of 
cytology, colposcopy with biopsy if needed and HPV testing. Only patients with at least two cytology 
smears and one HPV test during the first two post-treatment years remained in the study. The end-point 
of the study was a secondary treatment (reconization or hysterectomy) or disease free period of at least 
24 months. Indication for a second treatment was based on a positive cytology smear (HSIL/AGC/AIS) 
and unsatisfactory or positive colopscopy finding. The cytology smear was taken using liquid based 
cytology (LBC) ThinPrep© (Hologic, Inc Corp. Mariborough, MA) or the conventional Papanicolaou. 
Cervical smears were classified according to the Bethesda System 2006 - Zagreb modification and 
dichotomized into positive (≥H-SIL/AGC/AIS) or negative [7]. Since HPV testing was used for the 
evaluation of the current follow-up policy, test results were blinded until the analysis. The HPV test 
was performed by EIA PCR using a HPV-general-primer-mediated PCR. A β-globin PCR was 
performed to ascertain the quality of the target DNA. All 14 high-risk HPV types (16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59, 66 and 68) were tested for in one assay. Where possible, genotyping was 
performed before conization by Line immuno Probe Assay (Inno-LiPA) genotyping v2 system 
(Innogenetics, Gent, Belgium). 
The statistic analysis was performed using the χ
2
 test in analysis of frequency tables for 
independent categorical variables. Additionally, McNemar’s test for trends was used to assess follow-
up differences. Kappa coefficients (k=coefficient of agreement) were calculated to analyze 
consistencies and agreement between test results during the follow-up period. Performance indicators 
and diagnostic accuracy were calculated using the contingency tables for sensitivity, specificity, 
positive (PPV) and negative predictive value (NPV), with corresponding 95% confidence intervals 
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(CI). In all tests P values below 0.05 were regarded as statistically significant. Calculations were 
performed using the StatsDirect Statistical Software version 2.7.8 (www.statsdirect.com). 
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Results 
Data was analyzed for 114 patients, since 21 were lost to follow-up. The median follow-up 
time was 41 months (5-72 months). Cone histology showed CIN3 in 101 (88.6%) and AIS in 13 
(11.45%) patients. In six patients with AIS there were also CIN3 changes (46.2%). Most of the patients 
were younger than 40 (64.9%; median 35.0, interquartile range 30.0-43.3; range 18–66 years) and 31 
(27.2%) patients were nulliparous prior to conization. Histology diagnosis (CIN3/AIS) didn’t differ 
significantly between age groups (P=0.402) however, the number of women younger than 30 was more 
frequent in the AIS group (38.5% vs 21.8%). All of the women that had HPV testing before conization 
(N=39) were HPV positive. Thirty-one (79.5%) patients had a monoinfection, but a multiple infection 
was more common in patients younger than 40 (P=0.045). The most common genotype isolated was 
HPV16 in both types of infection, being present in 25 (64.2%) patients. Genotype distribution was 
related to histology since HPV18 had only been isolated in AIS specimens (P=0.036). 
The primary treatment was by cold-knife conization in 98 (86%) and LLETZ in 16 (14%) 
patients. Positive margins were found in 20 (17.5%) cone specimens and were more common in the 
LLETZ group (P=0.024). During the follow-up 11 (9.6%) patients had a second surgery due to a 
suspicion of residual/recurrent disease. In four patients reoperation was done (36.4%) during the first 
six months after conization and in seven (63.6%) during the following 18 months. Four (36.4%) 
patients had hysterectomy and seven (63.6%) had reconization done. Histology revealed no evidence of 
preinvasive or invasive diseases in five (45.5%) of these patients. Four patients were confirmed with 
CIN 2,3 and two had an invasive carcinoma. 
Margin involvement was not related to a decision to perform a second treatment (P=0.084). 
Still, in patients with positive cytology those with involved margins were more likely to have a 
residual/recurrent disease (P=0.022). There was no correlation between the type of HPV infection 
before conisation and the residual/recurrent disease (P=0.581).  
Figure 1 shows distribution of positive cytology and HPV during the follow-up. The highest 
frequency of positive cytology smears was in the 3-6 month interval (P<0.001). There was no 
difference in HPV test results distribution between follow-up intervals. In all three intervals HPV test 
was more frequently positive than cytology smears and the biggest difference was in the 18-24 month 
interval (P=0.010). There was a high concordance of cytology and HPV test results during the whole 
follow-up period (Fig. 2). Cytology smears were most consistent between 3-6 month and 9-12 month 
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intervals (k=0.458, P<0.001). HPV test results between follow-up intervals were inconsistent and had a 
low coefficient of agreement. Best agreement was found between HPV at 3-6 month interval and 
cytology at 9-12 month interval follow-up (k=0.559, P<0.001). 
Both cytology (P<0.001) and HPV test (P=0.015) results correlated with a decision to perform 
a second treatment. Cytology had a PPV of 61.1% (CI 35.8-82,7), a NPV of 100% (CI 96.3-100), 
whereas HPV test had a PPV of 21.4% (CI 8.3-41), a NPV of 94.2% (CI 87-98.1). The performance of 
cytology and HPV test in detecting a residual/recurrent disease is shown in Table 2. There was no 
residual/recurrent disease when posttreatment cytology or HPV test was negative. In the group of 
patients with positive cytology 33.3% had a residual/recurrent disease, whereas among those HPV 
positive 21.4% had a residual/recurrent disease. All of the patients who had a residual/recurrent disease 
were HPV positive, and 75% of disease-free patients were HPV negative. 
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Discussion and conclusion  
Women treated for a preinvasive cervical disease are mostly of reproductive age and still 
desire pregnancy, as were the majority of women in our study, therefore the approach in treatment and 
follow-up has to be safe and sparing. Negative follow-up test results whether it’d be only cytology, 
only HPV or a combined test, give a reassuring low risk of 5-year recurrence of CIN2+ lesion [8]. In 
our study both cytology and HPV showed a good performance in detecting a residual/recurrent disease 
(Table 2) with sensitivity of 100% and NPV of 100% for both tests. Women not reoperated remained 
disease free up to 72 months (4-7 years) after conization. However, in the reoperated group 45.5% had 
no residual/recurrent disease in the histology report. We can argue that these patients were 
unnecessarily exposed to peri- and postoperative morbidity. Some other studies also found a relatively 
high number of reoperated patients who had no residual/recurrent disease confirmed [4,9]. The decision 
for a second treatment in our study relied upon cytology and colposcopy protocol, mainly (81.2%) 
during the first year of follow-up. Histology reports were mostly negative in those reoperated 6 months 
after conization, which confirms findings of some other authors that this protocol is more often false-
positive in the early follow-up period [10].  
During the whole follow-up period the concordance of cytology and HPV test results was high 
(Fig. 2) and almost 70% of patients had both tests negative, which corresponds to results of other 
studies (14). Given the high sensitivity and concordance in our results we conclude that in our setting 
(with poorer resources and high quality cytology) it is not cost-effective to perform both tests to all 
women after conization. Gok et al suggested that patients at the highest risk for residual/recurrent 
disease are those with HPV16 infection prior to conization and that they should have a combined test 
done 6 months after conization [11]. Considering that HPV infection is alluded in biopsy proven 
CIN/AIS lesions and the fact that most women in our study tested before conization had HPV16 and/or 
18 positive (74.5%), we don’t think genotyping improves the quality of follow-up but only raises the 
cost. Given that HPV test results between follow-up intervals in our study had a low coefficient of 
agreement and that natural history of viral infection depends on individual’s characteristics [12] it is 
questionable if we can rely on one-fold testing without the reassurance of cytology. The highest 
incidence of a positive HPV test was during the second year of follow-up (P=0.010), which can be 
explained by individual’s sexual behavior. Protocols including the HPV test have shown that the 
optimal HPV clearance after conization is 6 months posttreatment [13]. 
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Many studies have shown that combined testing has the highest sensitivity in detecting a 
residual/recurrent disease [14]. According to our results both tests show a very good performance in 
detecting a residual/recurrent disease so depending on the socio-economic aspect both can be used as a 
primary follow-up tool after conization. In our study specificity of cytology (88.9%) was higher than of 
HPV (79.6%) in detecting a residual/recurrent disease thus the choice of cytology as the first follow-up 
test after conization in our setting is obvious, whereas others can choose the HPV test instead. In each 
case if the chosen test is positive the other one has to be performed as well before deciding on a further 
procedure. In our study HPV test would have improved the specificity of cytology/colposcopy-based 
protocol in the group of reoperated patients since all of the patients with proven residual/recurrent 
disease were HPV positive whilst those with negative histology were HPV negative. Time interval 
from conization didn’t influence test performance in this group (P<0.001). In all follow-up intervals in 
case of positive cytology and/or inconclusive colposcopy a negative HPV test can give reassurance and 
reduce anxiety without hurrying with a second treatment but repeating the cytology smear in another 3-
4 months, considering that there is no suspicion of invasive disease. In these cases LBC has advantage 
compared to conventional PAP smear since there is no need to invite the patients for another visit.   
The follow-up after conization must ensure safety and reassurance of both patients and 
gynecologists, but at the same time it must be cost-effective. Mentioned downfalls of surveillance tools 
can lead to overtreatment therefore, if cytology or HPV is positive we strongly recommend that the 
other test be performed as well before any other procedure. Results of our study suggest that in our 
setting the best approach is to have a first control cytology smear six months after conization. HPV test 
should be done in patients with a positive smear any time during follow-up as the point of decision for 
a second treatment. With this approach we could considerably decrease the number of reoperated 
patients and co-morbidities without decreasing the quality of follow-up. 
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Fig. 1. The percentage of positive cytology smears and HPV tests during the follow-up 
 
Fig. 2. Distribution of concordant and non-concordant test results during the follow-up 
 
Table 1. Distribution of reoperated patients during the follow-up 
 
Case no. 
Age at 
conization 
PHD 1 
Cytology 
prior to 2nd 
treatment 
HPV infection 
prior to 2nd 
treatment 
Interval 
between 
treatments 
(months) 
PHD 2 
1 38 CIN 3 HSIL Positive 11 Positive 
2 31 CIN3 HSIL Positive 10 Positive 
3 44 CIN3 HSIL Negative 11 Negative 
4 43 CIN3 HSIL Positive 7 Positive 
5 46 CIN3 HSIL Negative 5 Negative 
6 54 CIN3 HSIL Positive 24 Positive 
7 37 AIS AGC Negative 5 Negative 
8 31 AIS HSIL, AGC Positive 19 Positive 
9 43 AIS HSIL, AIS Negative 5 Negative 
10 31 AIS AGC Negative 5 Negative 
11 38 CIN3 HSIL Positive 8 Positive 
 
Table 2. Performance of cytology and HPV test in detection of residual/recurrent disease 
 
 Cytology % (CI) HPV % (CI) 
Sensitivity 100 (54.1-100) 100 (54.1-100) 
Specificity 88.9 (81-94.1) 79.6 (70.8-86.8) 
PPV 33.3 (13.3-59) 21.4 (8.3-41) 
NPV 100 (96.2-100) 100 (95.8-100) 
0,0%
5,0%
10,0%
15,0%
20,0%
25,0%
30,0%
3-6 months 9-12 months 18-24 months
HPV
Cytology
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